CoQ10, vigor and fatigue
What studies of vigor and subjective fatigue in healthy adults showed.
Key points
- In an eight-week study of healthy adults aged 40 and over, neither ubiquinone nor ubiquinol showed a convincing advantage over placebo in vigor. No confirmed improvement in vigor was shown for these forms and duration. [1] See the evidence 1
- A pooled analysis of three studies in healthy adults found no convincing reduction in subjective fatigue. These data do not establish a reliable reduction in fatigue in this group. [2] See the evidence 1
Practical guide
Check the conclusions and whether they apply to your situation.
Vigor, vitality and fatigue were measured separately.
Key points
Why these conclusions
Study results
In a trial of healthy adults aged 40 and over, separate groups took 200 mg of ubiquinone or ubiquinol with food or placebo for eight weeks. No convincing advantage in vigor, vitality or general health rating was found. [1]
A pooled analysis of three studies in healthy adults found no convincing reduction in subjective fatigue. The studied preparations and durations varied. [2]
In healthy adults aged 40 and over, neither ubiquinone nor ubiquinol showed a convincing advantage in vigor ratings over eight weeks.
| Parameter | Data |
|---|---|
| Result | In healthy adults aged 40 and over, neither ubiquinone nor ubiquinol showed a convincing advantage in vigor ratings over eight weeks. No significant advantage was reported. The main text gives p>0.44 for secondary outcomes; the abstract gives p>0.16. |
| Participants | 150 healthy adults aged 40 and over allocated to five groups |
| Form | 200 mg/day ubiquinone or 200 mg/day ubiquinol, separate groups, with food |
| Dose | 200 mg/day ubiquinone or 200 mg/day ubiquinol, separate groups, with food |
| Dose basis | 200 mg/day ubiquinone or 200 mg/day ubiquinol, separate groups, with food |
| Comparator | Placebo |
| Duration | 8 weeks |
| Confidence | 2/4: Precision: Exact confidence intervals for each form versus placebo were not extracted. Consistency: No grounds for a separate downgrade. Applicability to the specified group: The study tested the stated form, participant group and outcome. Possible publication bias: No specific data for a separate downgrade. Study methods: Multiple secondary measures in five groups. |
| Evidence base | 1 trial; outcome from the same participant group |
| Sources | [1] |
Ubiquinone and ubiquinol did not show a convincing advantage over placebo in vitality ratings.
| Parameter | Data |
|---|---|
| Result | Ubiquinone and ubiquinol did not show a convincing advantage over placebo in vitality ratings. No significant advantage was reported. The main text gives p>0.44 for secondary outcomes; the abstract gives p>0.16. |
| Participants | 150 healthy adults aged 40 and over allocated to five groups |
| Form | 200 mg/day ubiquinone or 200 mg/day ubiquinol, separate groups, with food |
| Dose | 200 mg/day ubiquinone or 200 mg/day ubiquinol, separate groups, with food |
| Dose basis | 200 mg/day ubiquinone or 200 mg/day ubiquinol, separate groups, with food |
| Comparator | Placebo |
| Duration | 8 weeks |
| Confidence | 2/4: Precision: Exact confidence intervals for each form versus placebo were not extracted. Consistency: No grounds for a separate downgrade. Applicability to the specified group: The study tested the stated form, participant group and outcome. Possible publication bias: No specific data for a separate downgrade. Study methods: Multiple secondary measures in five groups. |
| Evidence base | 1 trial; outcome from the same participant group |
| Sources | [1] |
Ubiquinone and ubiquinol did not show a convincing advantage over placebo in general health ratings.
| Parameter | Data |
|---|---|
| Result | Ubiquinone and ubiquinol did not show a convincing advantage over placebo in general health ratings. No significant advantage was reported. The main text gives p>0.44 for secondary outcomes; the abstract gives p>0.16. |
| Participants | 150 healthy adults aged 40 and over allocated to five groups |
| Form | 200 mg/day ubiquinone or 200 mg/day ubiquinol, separate groups, with food |
| Dose | 200 mg/day ubiquinone or 200 mg/day ubiquinol, separate groups, with food |
| Dose basis | 200 mg/day ubiquinone or 200 mg/day ubiquinol, separate groups, with food |
| Comparator | Placebo |
| Duration | 8 weeks |
| Confidence | 2/4: Precision: Exact confidence intervals for each form versus placebo were not extracted. Consistency: No grounds for a separate downgrade. Applicability to the specified group: The study tested the stated form, participant group and outcome. Possible publication bias: No specific data for a separate downgrade. Study methods: Multiple secondary measures in five groups. |
| Evidence base | 1 trial; outcome from the same participant group |
| Sources | [1] |
A pooled analysis of three studies in healthy adults found no convincing reduction in subjective fatigue.
| Parameter | Data |
|---|---|
| Result | A pooled analysis of three studies in healthy adults found no convincing reduction in subjective fatigue. Hedges g −0.351 (95% CI −0.756 to +0.053). |
| Participants | Healthy adults, three studies in the subgroup |
| Form | Ubiquinol in the Morikawa and Mizuno studies; CoQ10 in the Mousavi study. |
| Dose | Morikawa: 100 mg/day; Mizuno: 100 or 150 mg/day; Mousavi: 200 mg/day. |
| Dose basis | Morikawa: 100 mg/day; Mizuno: 100 or 150 mg/day; Mousavi: 200 mg/day. |
| Comparator | Placebo in each of the three studies of healthy participants. |
| Duration | Morikawa: 8 weeks; Mizuno: 12 weeks; Mousavi: 4 weeks. |
| Confidence | 1/4: Precision: Small samples, intervals and uncertain clinical significance. Consistency: High heterogeneity. Applicability to the specified group: The stated form, outcome, clinical context and population limit transferability. Possible publication bias: Asymmetry or incomplete publications. Study methods: Limitations in assessing design, reporting or losses. |
| Evidence base | 3 studies for this outcome in the review |
| Sources | [2] |
More details
How to apply the results
The fatigue assessment relates to healthy adults in three studies; their doses and durations are shown in the evidence card. [2]
Sources
- A Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Effects of Commercially Available Ubiquinone, Ubiquinol, and Geranylgeraniol Dietary Supplements on Plasma CoQ10 Concentrations. https://doi.org/10.1155/jnme/5589963
- Effectiveness of Coenzyme Q10 Supplementation for Reducing Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.883251/full
Methodology: Subpages evidence-led supplement pipeline v1